DHAP plus filgrastim as an effective peripheral stem cell mobilization regimen for autologous stem-cell transplantation in patients with relapsed/refractory lymphoma: A single center experience
TRANSFUSION AND APHERESIS SCIENCE, cilt.54, sa.1, ss.48-52, 2016 (SCI-Expanded, Scopus)
- Yayın Türü: Makale / Tam Makale
- Cilt numarası: 54 Sayı: 1
- Basım Tarihi: 2016
- Doi Numarası: 10.1016/j.transci.2016.01.012
- Dergi Adı: TRANSFUSION AND APHERESIS SCIENCE
- Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
- Sayfa Sayıları: ss.48-52
- Anahtar Kelimeler: DHAP plus filgrastim, Stem cell mobilization, Lymphoma, HIGH-DOSE CYCLOPHOSPHAMIDE, COLONY-STIMULATING FACTOR, NON-HODGKINS-LYMPHOMA, BLOOD STEM, G-CSF, RANDOMIZED-TRIAL, PROGENITOR CELLS, SALVAGE THERAPY, NORMAL DONORS, DISEASE
- İnönü Üniversitesi Adresli: Evet
Özet
This study aimed to evaluate the efficiency of DHAP regimen plus filgrastim for mobilization of stem cells in patients with recurrent and/or refractory lymphoma. Thirty-four patients who took DHAP as salvage therapy prior to autologous stem cell transplantation were included. After chemotherapies, 2 cycles of DHAP plus filgrastim were administered to the patients. Stem cells from 32 patients (94%) were collected on median 11th day (8-12), and the median collected CD34(+) cell dose was 9.7 x 10(6)/kg (range 3.8-41.6). DHAP plus filgrastim was found to be an effective chemotherapy regimen in mobilizing CD34(+) stem cells into the peripheral. (c) 2016 Elsevier Ltd. All rights reserved.